ARON-3 Study: International Multicentric Retrospective Study to Collect Global Experiences in the Treatment of Patients With Metastatic PCa
Recruiting now
Conditions studied: Prostate Cancer
In brief
Study wants to explore real-world data in three distinct settings * Patients with metachronous or de novo mCSPC treated with ADT+ARSI or ADT+ARSI+docetaxel \_ARON-3S * Patients receiving Lutetium-177 PSMA for mCRPC \_ ARON-3Lu * Patients treated with PARP inhibitors (alone or combined with ARSI) for CRPC \_ ARON-3GEN
Key facts
- Study ID
- NCT06200558
- Run by
- Hospital of Macerata
- People needed
- 534
- Starts
- 2024-01-31
- Expected to finish
- 2028-02-01
- Last updated by the study team
- 2025-11-26
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patients aged >18y
- Cytological or Histologically confirmed diagnosis of PC
- Histologically or radiologically confirmed diagnosis of metastatic disease and
- For ARON-3S
- ▪ Treatment with ADT + Apalutamide or ADT + enzalutamide or ADT + Abiraterone or ADT + Abiraterone + Docetaxel or ADT + Darolutamide + Docetaxel (patients treated with previous docetaxel - CHAARTED - resulted eligible)
- For ARON-3Lu
- ▪ Treatment with Luthetium-177-PSMA therapy for castration resistant PC
- For ARON-3GEN
- HRD POSITIVE STATUS
- Treatment with PARP inhibitors for castration resistant PC. Treatment included: olaparib (as 1st, 2nd or 3rd line therapy), olaparib + abiraterone (as 1st line therapy) or niraparib + abiraterone (as 1st line therapy) or talazoparib + enzalutamide
You may not qualify if…
- Patients without histologically confirmed diagnosis of PC
- Patients without histologically or radiologically confirmed metastatic disease and
- For ARON-3S
- ▪ Patients treated with doublets or triplets not included in the list reported in the Inclusion Criteria Section
- For ARON-3Lu
- ▪ Patients treated with Luthetium-177-PSMA therapy for hormone/castration sensitive PC
- For ARON-3GEN
- HRD NEGATIVE STATUS
- Patients treated with PARP inhibitors alone or in combination regimens not included in the ARON-3GEN study
Where it is running
- Ospedale di Macerata — Province of Macerata, Macerata, Italy (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.